Triamcinolone acetonide ointment/cream
Generic name
Triamcinolone acetonide ointment/cream
Brand name
ATC Code
D07AB09
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Atopic dermatitis |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Children may be more sensitive to glucocorticoids than adults because of their greater skin surface area in relation to their weight. This can lead to increased absorption in children, which can lead to systemic effects: Suppression of the hypothalamic-pituitary adrenal axis, Cushing's syndrome, and increased intracranial pressure. In children, hypofunction of the adrenal cortex may result in short stature, delayed weight gain, low plasma cortisone levels, and lack of response to the ACTH stimulation test. Consequences of increased intracranial pressure include fontanel bulging, headache, bilateral papilledema. (SmPC Volon A)
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
In infants, the nappy can act as the enclosing dressing and thus increase the absorption. In children, inhibition of the adrenal cortex can occur fairly quickly. In addition, the secretion of growth hormone can be suppressed in them. It is therefore recommended that the height and weight should be checked regularly if prolonged use is required. Careful consideration is needed when applied to the eyelids because of the possibility of contaminating the conjunctiva (and the risk of glaucoma simplex or subcapsular cataracts occurring) on the one hand, and the risk of corneal damage due to the continuous rubbing/scratching of untreated eczema on the other.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
CORTICOSTEROIDS, PLAIN
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Corticosteroids, weak (group I) | ||
|---|---|---|
| D07AA02 | ||
| Corticosteroids, moderately potent (group II) | ||
|---|---|---|
| D07AB01 | ||
| D07AB02 | ||
| Corticosteroids, potent (group III) | ||
|---|---|---|
| D07AC01 | ||
| D07AC03 | ||
| D07AC17 | ||
| D07AC14 | ||
| D07AC13 | ||
| D07AC18 | ||
| Corticosteroids, very potent (group IV) | ||
|---|---|---|
| D07AD01 | ||
References
- Krakowski AC, et al, Management of Atopic Dermatitis in the Pediatric Population, Pediatrics, 2008, Vol. 122 No. 4, 812-824
- CBO, Richtlijn Constitutioneel Eczeem, www.cbo.nl, Maart 2015
- NHG, Standaard constitutioneel exceem (M37), www.nhg.nl, augustus 2006
- Dirven-Meijer PC et al, NHG standaard Eczeem, Huisarts Wet, 2014, 57(5), 240-52
Changes
Therapeutic Drug Monitoring
Overdose
